

observation period (14 days). According to the K.K. Sidorov's classification, which is recommended by the State Pharmacological Center of the Ministry of Health of Ukraine, the studied extract of golden marigold herb can be classified as class V, i.e. almost non-toxic substances ($LD_{50} > 5000$ mg/kg).

Matushchak M.R.

THE ANALYSIS RESULTS OF MEDICAL PRESCRIPTIONS AND DRUG CONSUMPTION IN PATIENTS WITH LYMPHOGRANULOMATOSIS IN UKRAINE

Department of Pharmaceutical Botany and Pharmacognosy

Bukovinian State Medical University

The effective treatment organization of patients with Hodgkin's lymphoma requires significant costs, which in most countries are reimbursed by public funds or social health insurance programs. This is due to the high cost of chemotherapy regimens that have been used for a long time. Given the global trends in the medical care cost and drug expenses used in the treatment of cancer patients lead to the arising issues concerning development and introduction of rational models of pharmaceutical support for patients with Hodgkin's lymphoma.

Ukraine is no exception, where in the 2000s the main elements of control strategy for rational use of limited resources was the use of health technology assessment. One of the tools is clinical and economic analysis, namely frequency and structural analysis of drug consumption by different patient groups. The analysis results are the basis for effective management decisions in rational usage of health resources.

The aim of the study was to analyze medical prescriptions and the structure of drug consumption in patients with lymphogranulomatosis in Ukraine. The patients' medical records (455) with lymphogranulomatosis were studied. The historical, analytical, comparative, systemic, logical, hypothetical, deductive, graphical methods of scientific research, as well as clinical and economic analyses were used.

The study results were the following: on average, the patients were found to be in the hospital for 32 sick-days and they received 16,835 medical prescriptions. There were 37 prescriptions per patient. The first place in the prescriptions occupied drugs from groups L – Antineoplastic and immunomodulating agents, B – drugs affecting the blood system and hematopoiesis, and A – drugs affecting the digestive system and metabolism. These groups of drugs accounted for more than half of medical prescriptions (9247 or 54.93%). The prescription structure was dominated by drugs in the form of solutions or powders (62.78% of all prescriptions or 10569). In accordance with the II level of the ATC classification, the first three positions in prescriptions were occupied by drugs used in the chemotherapy and elimination of exacerbation symptoms of chronic pathologies. These drugs were from the following groups: L01 – antineoplastic and immunomodulating agents (12.80% or 2154 prescriptions), B05 – blood substitutes and perfusion solutions (11.95 % or 2012, respectively), C01 – drugs for the heart diseases treatment (9.99 % or 1681, respectively). Antineoplastic prescriptions ranged from 31 (L01C D01 – Paclitaxel) to 289 (L01DB01 – Doxorubicin) ones. The most prescribed drugs were L01DB01 – doxorubicin, AA01 – cyclophosphamide, and L01CB01 – etoposide. It was proven that patients with lymphogranulomatosis received an average of 8.3 prescriptions of antitumor drugs. The general indicator of the drug consumption was 23440.30 thousand UAH or 822.58 thousand US dollars, which, in terms of one patient, amounted to 51517.14 UAH or 1807.86 US dollars. It was found that 38797.60 UAH or 1361.50 USD were spent on the effective chemotherapy and maintenance of the patient's body, which was 8.21 and 17.1 times more than the minimum wage and living wage according to the data presented in the state budget for 2020 in Ukraine.

Thus, medical prescriptions and drug consumption by patients with lymphogranulomatosis have been found to reflect the nature of the therapy, namely the need for intensive chemotherapy courses, polymorbidity of patients as well as the severity of the pathological process. Considering the high treatment cost, the solution to the increase its availability level requires a systemic solution in various directions.